Prosecution Insights
Last updated: October 02, 2026
Application No. 18/570,579

Self-Assembling Nanoparticles Based On Amphiphilic Peptides for Drug Delivery Applications

Non-Final OA §102§112
Filed
Dec 14, 2023
Priority
Jun 16, 2021 — provisional 63/211,336 +2 more
Examiner
DAVIS, BRIAN J
Art Unit
1614
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
United States Department of Health and Human Services
OA Round
1 (Non-Final)
85%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
81%
With Interview

Examiner Intelligence

Grants 85% — above average
85%
Career Allowance Rate
1348 granted / 1589 resolved
+24.8% vs TC avg
Minimal -4% lift
Without
With
+-4.0%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 9m
Avg Prosecution
47 currently pending
Career history
1625
Total Applications
across all art units

Statute-Specific Performance

§101
5.2%
-34.8% vs TC avg
§103
16.5%
-23.5% vs TC avg
§102
19.7%
-20.3% vs TC avg
§112
44.7%
+4.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1589 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restriction Inventor’s election, without traverse, of the claims of Group I as the group elected to begin prosecution is acknowledged. The election/restriction is hereby made FINAL. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 77 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. In the penultimate diagramed structure of the claim, the moiety L2B is unclear because it is undefined. Furthermore, the text which accompanies the diagramed structure inexplicably defines a variable L2A which is not present in the structure. Clarification is in order. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim 1, 4, 6, 62, 81 and 86 are rejected under 35 U.S.C. 102(a)(1) as being clearly anticipated by US 2018/0221277 A1. The reference teaches a composition comprising amphiphilic dendron-coil micelles for the transdermal delivery of encapsulated drugs (abstract; page 2, [0011]; page 5, [0061]). A wide variety of drugs may be encapsulated such as anticancer drugs and anti-inflammatory drugs (page 5, [0062]ff). The reference further teaches (page 2, [0016]) that each amphiphilic dendron-coil comprises a hydrophobic core-forming block, a polyester dendron and a PEG moiety. A non-peptidyl hydrophobic core-forming block is, for instance, PCL, PLA, PGA or PLGA. The polyester dendron is, for example, a 3-5 generation polyester dendron with either an acetylene or carboxylate core. The PEG is moiety is, for example, a methoxy PEG, an amine-terminated PEG, an acetylated PEG, a carboxylated PEG, thiol-terminated PEG, an N-hydroxysuccinimide-activated PEG, a NH2-PEG-NH2, or NH2-PEG-COOH moiety. (This basic prior art structure corresponds to a S-H structure of the instant claim set.) With respect to claim 6, the examiner notes that during patent examination the pending claims must be given their broadest reasonable interpretation consistent with the specification. (See MPEP 2111.) That being the case, given the broad definitions of FG1 (“…a first functional group…”) and FG2 (“…a second functional group…”), the limitations of claim 6 may be defined as, essentially, almost anything. Allowable Subject Matter Claims 10-13, 15, 18, 25, 28, 29, 32, 47 and 80 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure: US 2014/0037747 A1 is an earlier PGPub in which Seungpyo Hong is also an inventor and the trustees of the University of Illinois are also the applicant, and whose teachings are similar to those of US 2018/0221277 A1 above. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN J DAVIS whose telephone number is (571)272-0638. The examiner can normally be reached M-F 8:30-5:00 PM EDT. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush, can be reached at 571-272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN J DAVIS/Primary Examiner, Art Unit 1614 8/29/2026
Read full office action

Prosecution Timeline

Dec 14, 2023
Application Filed
Sep 02, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12747253
KRAS G12D INHIBITORS
3y 8m to grant Granted Sep 29, 2026
Patent 12746193
COSMETIC COMPOSITION
2y 9m to grant Granted Sep 29, 2026
Patent 12746293
DNA Vector Delivery Using Lipid Nanoparticles
2y 10m to grant Granted Sep 29, 2026
Patent 12746263
COMPOSITION FOR TREATMENT OF AUTOIMMUNE DISEASES COMPRISING LACTOBACILLUS SAKEI OR EXTRACELLULAR VESICLES DERIVED THEREFROM AS ACTIVE INGREDIENT
2y 9m to grant Granted Sep 29, 2026
Patent 12746278
COMPOSITIONS AND METHODS FOR WOUND HEALING
2y 3m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
85%
Grant Probability
81%
With Interview (-4.0%)
1y 9m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1589 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month